Suppr超能文献

重新审视促红细胞生成素在眼部疾病治疗中的作用。

Revisiting the role of erythropoietin for treatment of ocular disorders.

作者信息

Shirley Ding S L, Leow S N, Munisvaradass R, Koh E H, Bastion M L C, Then K Y, Kumar S, Mok P L

机构信息

Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, UPM Serdang, Selangor, Malaysia.

Department of Ophthalmology, Hospital Sultanah Aminah, Johor Bahru, Malaysia.

出版信息

Eye (Lond). 2016 Oct;30(10):1293-1309. doi: 10.1038/eye.2016.94. Epub 2016 Jun 10.

Abstract

Erythropoietin (EPO) is a glycoprotein hormone conventionally thought to be responsible only in producing red blood cells in our body. However, with the discovery of the presence of EPO and EPO receptors in the retinal layers, the EPO seems to have physiological roles in the eye. In this review, we revisit the role of EPO in the eye. We look into the biological role of EPO in the development of the eye and the physiologic roles that it has. Apart from that, we seek to understand the mechanisms and pathways of EPO that contributes to the therapeutic and pathological conditions of the various ocular disorders such as diabetic retinopathy, retinopathy of prematurity, glaucoma, age-related macular degeneration, optic neuritis, and retinal detachment. With these understandings, we discuss the clinical applications of EPO for treatment of ocular disorders, modes of administration, EPO formulations, current clinical trials, and its future directions.

摘要

促红细胞生成素(EPO)是一种糖蛋白激素,传统上认为它仅负责在我们体内产生红细胞。然而,随着视网膜各层中促红细胞生成素(EPO)及其受体的发现,EPO似乎在眼睛中具有生理作用。在这篇综述中,我们重新审视EPO在眼睛中的作用。我们研究EPO在眼睛发育中的生物学作用及其所具有的生理作用。除此之外,我们试图了解EPO导致各种眼部疾病(如糖尿病性视网膜病变、早产儿视网膜病变、青光眼、年龄相关性黄斑变性、视神经炎和视网膜脱离)治疗和病理状况的机制和途径。基于这些认识,我们讨论EPO在眼部疾病治疗中的临床应用、给药方式、EPO制剂、当前的临床试验及其未来方向。

相似文献

1
Revisiting the role of erythropoietin for treatment of ocular disorders.
Eye (Lond). 2016 Oct;30(10):1293-1309. doi: 10.1038/eye.2016.94. Epub 2016 Jun 10.
2
Use of erythropoietin in ophthalmology: a review.
Surv Ophthalmol. 2022 Mar-Apr;67(2):427-439. doi: 10.1016/j.survophthal.2021.06.002. Epub 2021 Jun 23.
3
Erythropoietin in diabetic retinopathy.
Vision Res. 2017 Oct;139:237-242. doi: 10.1016/j.visres.2017.05.010. Epub 2017 Aug 8.
4
The Latest Evidence of Erythropoietin in the Treatment of Glaucoma.
Int J Mol Sci. 2022 Dec 16;23(24):16038. doi: 10.3390/ijms232416038.
5
Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy.
Endocrine. 2012 Apr;41(2):220-6. doi: 10.1007/s12020-011-9579-6. Epub 2011 Dec 14.
7
Erythropoietin and retinopathy of prematurity.
Early Hum Dev. 2011 Mar;87 Suppl 1:S39-42. doi: 10.1016/j.earlhumdev.2011.01.027.
8
Erythropoietin and the nervous system.
Brain Res. 2004 Mar 12;1000(1-2):19-31. doi: 10.1016/j.brainres.2003.12.037.
9
Erythropoietin: a hormone with multiple functions.
Pathobiology. 2011;78(1):41-53. doi: 10.1159/000322975. Epub 2011 Apr 5.
10
Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy.
Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1329-35. doi: 10.1167/iovs.08-2521. Epub 2008 Oct 24.

引用本文的文献

1
Topical erythropoietin in the management of scleral necrosis: a narrative review.
Ther Adv Ophthalmol. 2025 Sep 2;17:25158414251365749. doi: 10.1177/25158414251365749. eCollection 2025 Jan-Dec.
2
Neuroprotective Effect of Methylene Blue in a Rat Model of Traumatic Optic Neuropathy.
Pharmaceuticals (Basel). 2025 Jun 19;18(6):920. doi: 10.3390/ph18060920.
3
Methanol toxicity; characteristics, ophthalmological sequelae and recommended treatment.
Eye (Lond). 2025 Apr;39(6):1023-1025. doi: 10.1038/s41433-025-03628-1. Epub 2025 Feb 20.
6
Rationale of Basic and Cellular Mechanisms Considered in Updating the Staging System for Diabetic Retinal Disease.
Ophthalmol Sci. 2024 Mar 27;4(5):100521. doi: 10.1016/j.xops.2024.100521. eCollection 2024 Sep-Oct.
7
Cognitive Impairment in Multiple Sclerosis.
Bioengineering (Basel). 2023 Jul 23;10(7):871. doi: 10.3390/bioengineering10070871.
9
Intraocular Sustained Release of EPO-R76E Mitigates Glaucoma Pathogenesis by Activating the NRF2/ARE Pathway.
Antioxidants (Basel). 2023 Feb 23;12(3):556. doi: 10.3390/antiox12030556.

本文引用的文献

1
Safety and Efficacy of Human Wharton's Jelly-Derived Mesenchymal Stem Cells Therapy for Retinal Degeneration.
PLoS One. 2015 Jun 24;10(6):e0128973. doi: 10.1371/journal.pone.0128973. eCollection 2015.
2
Carbamylated erythropoietin mediates retinal neuroprotection in streptozotocin-induced early-stage diabetic rats.
Graefes Arch Clin Exp Ophthalmol. 2015 Aug;253(8):1263-72. doi: 10.1007/s00417-015-2969-3. Epub 2015 Mar 1.
4
The protective effect of erythropoietin on the retina.
Ophthalmic Res. 2015;53(2):74-81. doi: 10.1159/000369885. Epub 2015 Jan 14.
5
Evidence That Erythropoietin Modulates Neuroinflammation through Differential Action on Neurons, Astrocytes, and Microglia.
Front Immunol. 2014 Oct 22;5:523. doi: 10.3389/fimmu.2014.00523. eCollection 2014.
7
Diabetic retinopathy risk factors: plasma erythropoietin as a risk factor for proliferative diabetic retinopathy.
Korean J Ophthalmol. 2014 Oct;28(5):373-8. doi: 10.3341/kjo.2014.28.5.373. Epub 2014 Sep 18.
8
Mesenchymal stem cells home to inflamed ocular surface and suppress allosensitization in corneal transplantation.
Invest Ophthalmol Vis Sci. 2014 Sep 16;55(10):6631-8. doi: 10.1167/iovs.14-15413.
9
Systemic administration of erythropoietin inhibits retinopathy in RCS rats.
PLoS One. 2014 Aug 13;9(8):e104759. doi: 10.1371/journal.pone.0104759. eCollection 2014.
10
Systemic treatment with erythropoietin protects the neurovascular unit in a rat model of retinal neurodegeneration.
PLoS One. 2014 Jul 11;9(7):e102013. doi: 10.1371/journal.pone.0102013. eCollection 2014.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验